Study for the regulation mechanism of acupuncture on brain-gut in patients with migraine

注册号:

Registration number:

ITMCTR1900002521

最近更新日期:

Date of Last Refreshed on:

2019-08-13

注册时间:

Date of Registration:

2019-08-13

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

针刺对偏头痛患者的脑-肠调控机制研究

Public title:

Study for the regulation mechanism of acupuncture on brain-gut in patients with migraine

注册题目简写:

English Acronym:

研究课题的正式科学名称:

针刺对偏头痛患者的脑-肠调控机制研究

Scientific title:

Study for the regulation mechanism of acupuncture on brain-gut in patients with migraine

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

81722050

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR1900025132 ; ChiMCTR1900002521

申请注册联系人:

倪夕秀

研究负责人:

赵凌

Applicant:

Xixiu Ni

Study leader:

Ling Zhao

申请注册联系人电话:

Applicant telephone:

+86 18408257571

研究负责人电话:

Study leader's telephone:

+86 13568801429

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

nixixiu@163.com

研究负责人电子邮件:

Study leader's E-mail:

ling94@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

四川省成都市金牛区十二桥路37号

研究负责人通讯地址:

四川省成都市金牛区十二桥路37号

Applicant address:

37 Twelve Bridge Road, Jinniu District, Chengdu, Sichuan, China

Study leader's address:

37 Twelve Bridge Road, Jinniu District, Chengdu, Sichuan, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

成都中医药大学

Applicant's institution:

Chengdu University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2019KL-030

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

四川中医药区域伦理审查委员会/成都中医药大学附属医院医学伦理委员会

Name of the ethic committee:

Sichuan Region Ethics Review Committee on Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2019/7/10 0:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

四川省成都市金牛区十二桥路37号

Contact Address of the ethic committee:

37 Twelve Bridge Road, Jinniu District, Chengdu, Sichuan, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

成都中医药大学

Primary sponsor:

Chengdu University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

四川省成都市金牛区十二桥路37号

Primary sponsor's address:

37 Twelve Bridge Road, Jinniu District, Chengdu, Sichuan, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川省

市(区县):

成都市

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

成都中医药大学

具体地址:

金牛区十二桥路37号

Institution
hospital:

Chengdu University of Traditional Chinese Medicine

Address:

37 Twelve Bridge Road, Jinniu District

经费或物资来源:

国家自然科学基金(优秀青年基金)(81722050)

Source(s) of funding:

National Natural Science Foundation of China (Excellent Youth Fund) (81722050)

研究疾病:

无先兆偏头痛

研究疾病代码:

Target disease:

migraine without aura

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

本研究以无先兆偏头痛患者为研究对象,利用肠道菌群测定技术观察无先兆偏头痛患者与健康受试者比较的肠道菌群种类和丰度特征,并结合fMRI对患者大脑结构和功能的检测结果,阐释无先兆偏头痛患者的脑-肠交互影响特征。在此基础上,观察针刺对无先兆偏头痛患者临床症状改善的同时,利用fMRI技术分别观察辨症针刺组、非穴组治疗前后对无先兆偏头痛患者大脑功能活动及功能连接网络的影响;利用肠道菌群指标分别分析辨症针刺与非穴针刺治疗对无先兆偏头痛患者肠道菌群的物种注释、物种组成分析、样本比较分析、物种差异分析等,比较辨症针刺与非穴针刺组对肠道菌群种类和丰度影响的共性与差异性,分别提取与无先兆偏头痛患者疗效改善密切相关的脑功能连接和肠道菌群生物学标记,分析患者大脑功能网络变化与肠道菌群调控的相关性,揭示针刺治疗无先兆偏头痛的脑-肠-微生物机制,并探索建立无先兆偏头痛针刺治疗疗效评估和预测模型,为临床治疗预后评估提供指导。

Objectives of Study:

In this study, patients with migraine without aura were used to study the gut microbiota species and abundance characteristics compared with healthy subjects, and combined with fMRI for brain structure and Functional test results, illustrating the brain-intestinal interaction characteristics of patients with migraine without aura. On this basis, observing acupuncture on the improvement of clinical symptoms in patients with migraine without aura,and using fMRI technique to observe the brain function and functional connection network of patients with aura without migraine before and after treatment in acupuncture group and non-acupoint group. Based on analyzing the effects of acupuncture and non-acupoint acupuncture on the intestinal flora, species composition, sample comparison, species difference of the intestinal flora of patients without migraine,comparing the commonality and difference of the effects of acupuncture and non-acupuncture groups on the species and abundance of intestinal flora and extracting brain function and intestinal flora biomarkers, which were closely related to the improvement of the efficacy of patients without migraine,to analyzing correlation between changes in brain function network and regulation of intestinal flora and revealing the brain-intestinal-microbial mechanism of acupuncture treatment on migraine without aura, and exploring the establishment of mode of effect and prediction on acupuncture treatment on migraine without aura for providing guidance of clinical treatment Prognostic assessment.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1.右利手;年龄在18-55岁之间,性别不限; 2.接受教育时间≥6年; 3.符合上述IHS的无先兆偏头痛诊断标准; 4.有1年以上偏头痛病史,偏头痛首发在50岁之前,在过去的1个月和基线期,头痛平均每月发作2-6次; 5.BAI标准分均小于36分,BDI标准分均小于21分; 6.患者本人签署知情同意书。

Inclusion criteria

1. Right hand; aged between 18-55 years, gender is not limited; 2. Education time >= 6 years; 3. Meet the above-mentioned IHS diagnostic criteria for aura without migraine; 4. There is a history of migraine for more than 1 year. The migraine first started before the age of 50. In the past 1 month and the baseline period, the average headache occurred 2-6 times per month; 5. BAI standard scores is less than 36 points, and BDI standard scores is less than 21 points; 6. The patient signed the informed consent form.

排除标准:

1.合并有头部外伤史、继发性头痛、紧张型头痛、间歇性头痛、丛集性头痛及心血管疾病、消化系统疾病的患者; 2.既往经历过主要肠道切除手术或胃肠道大手术者; 3.精神病患者,易合并感染及出血者,过敏体质者; 4.孕妇及哺乳期妇女; 5.不能理解或记录头痛日记; 6.过去3个月内患过中度便秘、腹泻; 7.过去1个月内因胆囊炎、消化道溃疡、尿路感染、急性肾盂肾炎、膀胱炎接受过药物治疗; 8.过去3个月内使用过抗生素,并持续3天或以上;或有长期服用镇痛药等药物习惯; 9.近3个月内接受过针刺治疗或其他预防性治疗; 10.体内有金属植入物,患有幽闭恐怖症等其他MRI检查禁忌者; 11.在MRI扫描中发现严重头颅解剖结构不对称或有明确病变; 12.3个月内参加过类似研究者。

Exclusion criteria:

1. Patients with a history of head trauma, secondary headache, tension headache, intermittent headache, cluster headache and cardiovascular disease, digestive system diseases; 2. Those who have experienced major bowel resection or major gastrointestinal surgery in the past; 3. Mental patients, susceptible to infection and bleeding, allergies; 4. Pregnant women and lactating women; 5. Can not understand or record the headache diary; 6. Suffering from moderate constipation and diarrhea in the past 3 months; 7. In the past 1 month, he received medical treatment for cholecystitis, peptic ulcer, urinary tract infection, acute pyelonephritis, cystitis; 8. Antibiotics have been used in the past 3 months for 3 days or more; or have long-term use of drugs such as analgesics; 9. Received acupuncture or other preventive treatment in the past 3 months; 10. There are metal implants in the body, and other MRI examination contrabands such as claustrophobia; 11. In the MRI scan, severe head anatomical structures were found to be asymmetric or have clear lesions; 12. Patient has participated in similar researchers within 3 months.

研究实施时间:

Study execute time:

From 2019-07-31

To      2022-12-31

征募观察对象时间:

Recruiting time:

From 2019-07-31

To      2022-12-31

干预措施:

Interventions:

组别:

健康对照组

样本量:

35

Group:

healthy control group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

治疗组

样本量:

35

Group:

Treatment group

Sample size:

干预措施:

针刺经穴

干预措施代码:

Intervention:

acupuncture

Intervention code:

组别:

对照组2

样本量:

35

Group:

control group 2

Sample size:

干预措施:

氟桂利嗪

干预措施代码:

Intervention:

Flunarizine

Intervention code:

组别:

对照组1

样本量:

35

Group:

control group 1

Sample size:

干预措施:

假针刺

干预措施代码:

Intervention:

sham-acupuncture

Intervention code:

样本总量 Total sample size : 140

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

四川省

市(区县):

成都市

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

成都中医药大学附属医院

单位级别:

三级甲等

Institution/hospital:

Teaching Hospital of Chengdu University of TCM

Level of the institution:

Teriary A Hospital

测量指标:

Outcomes:

指标中文名:

简易智能精神状态检查量表

指标类型:

次要指标

Outcome:

MMSE

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

贝克抑郁自评问卷

指标类型:

次要指标

Outcome:

BDI

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

头痛影响测试

指标类型:

主要指标

Outcome:

HIT-6

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胃肠道症状评定量表

指标类型:

主要指标

Outcome:

GSRS

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

头痛日记

指标类型:

主要指标

Outcome:

headche diary

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

简明健康生活质量量表

指标类型:

次要指标

Outcome:

SF-36

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肠道菌群数据采集及处理

指标类型:

主要指标

Outcome:

Intestinal flora data collection and processing

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

贝克焦虑量表

指标类型:

次要指标

Outcome:

BAI

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

功能磁共振

指标类型:

主要指标

Outcome:

fMRI

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

简式的McGill疼痛问卷表

指标类型:

主要指标

Outcome:

SF-MPQ

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

粪便

组织:

Sample Name:

stool

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 18
Min age years
最大 55
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

由1名研究人员采用SAS软件生成105例患者的随机数字表,根据其将所有符合纳入标准的患者随机分配到相应组别接受治疗。

Randomization Procedure (please state who generates the random number sequence and by what method):

One investigator used SAS software to generate a random number table of 105 patients, according to which all patients who met the inclusion criteria were randomly assigned to the appropriate group for treatment.

盲法:

对患者施盲。

Blinding:

Blind method for subjects.

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

暂未确定

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Not yet determined

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF表由研究人员进行采集并管理。临床数据采用SAS或SPSS统计分析系统进行统计,影像数据采用SPM软件、Matlab软件平台等进行分析

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF forms are collected and managed by researchers.The clinical data were statistically analyzed by SAS or SPSS statistical analysis system; the image data was analyzed by SPM software and Matlab software platform.

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above